We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte Corporation (INCY) - $25 value - yours FREE >>
Royalty Pharma PLC (RPRX) - $25 value - yours FREE >>
Ionis Pharmaceuticals, Inc. (IONS) - $25 value - yours FREE >>
Image: Bigstock
Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
Repros Therapeutics Inc. (RPRX - Free Report) is expected to report second quarter 2016 results on Aug 8. Let’s see how things are shaping up for this Zacks Rank #3 (Hold) stock.
Focus Remains on Pipeline
With Repros being a development-stage company, investors will remain focused on the company’s pipeline and cash burn. The company is focused on the development of treatments for hormonal and reproductive system disorders, and is currently working on filing for EU approval of enclomiphene for the treatment of patients with secondary hypogonadism in the fall of 2016. Repros will seek EU approval for enclomiphene through a central filing and expects a response regarding the candidate’s approval status by the fall of 2017.
Meanwhile, Repros is conducting a placebo-controlled, double-blind, proof-of-concept phase II study (ZA-205) on enclomiphene in obese secondary hypogonadal men to assess its impact on metabolic parameters and quality of life under a routine diet and exercise. Six-month data from this study are expected in the fall of 2016.
Apart from enclomiphene, the company has Proellex in its pipeline. It is being developed for the treatment of uterine fibroids and endometriosis.
REPROS THERAPEU Price
REPROS THERAPEU Price | REPROS THERAPEU Quote
Stocks that Warrant a Look
Here are some health care companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
The Earnings ESP for Ionis Pharmaceuticals, Inc. (IONS - Free Report) is +10.71% and it carries a Zacks Rank #2 (Buy). The company will release second-quarter results on Aug 9.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +300.00% and carries a Zacks Rank #2. It will be reporting second-quarter results on Aug 9.
Impax Laboratories Inc. has an Earnings ESP of +3.03% and carries a Zacks Rank #2. It will be reporting second-quarter results on Aug 9.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>